TGTX · NASDAQ · STOCK
TG Therapeutics (TGTX) Stock Analysis
$56.01
52W $26.76 – $59.30
59/100
$8.57B
18.4
1.66
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is TGTX Bullish or Bearish?
Bullish.
Innellis AI committee rates TG Therapeutics, Inc. (TGTX) Buy with a composite score of 59/100
, based on 6 analysts with 50% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.76 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.24 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 23.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Bollinger bandwidth of 23.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 58%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 72.3% shows genuine earnings power backing the valuation
− Price-to-book of 21.1x prices in significant intangible value
Growth Analyst
neutral
56
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Revenue growing 76.1% YoY -- genuine top-line momentum
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 23.8% signals elevated volatility
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 59.2 to 59.2.
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
60.7
Neutral
MACD Histogram
0.435
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$45.37
Resistance
$59.30
Bollinger %B
0.75
Inside Bands
Price vs Moving Averages
EMA 9
$55.36
Above
EMA 21
$53.94
Above
EMA 50
$51.97
Above
EMA 200
$42.82
Above
Fundamental Analysis
Valuation
62
Growth
6
Profitability
100
Financial Health
81
Cash Flow
15
Valuation
P/E Ratio
18.4×
P/B Ratio
13.14×
PEG Ratio
0.03
Dividend Yield
0.00%
52W High
$59.30
52W Low
$26.76
Quality & Growth
ROE
6900.7%
ROA
4205.8%
Gross Margin
8236.5%
Operating Margin
1705.1%
Revenue Growth YoY
—
Debt / Equity
1.25
AI Fundamental Assessment
P/E ratio of 18.4 (inexpensive relative to a 15-40x range); Price-to-book of 13.1x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 69.0%; Return on assets of 42.1%; Net margin of 55.2%; Gross margin of 82.4%; Current ratio of 4.27 (healthy short-term liquidity); Debt-to-equity of 1.25; Free cash flow per share is negative (-0.00); Most recent quarter missed estimates by 85.5%; 4 consecutive earnings misses; EPS growth decelerating (+28.6% -> -72.2% QoQ); Analyst estimates falling over recent quarters
Get the Full TGTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →